Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

Phase 1 Completed 12 enrolled University of Colorado, Denver National Institute of Mental Health (NIMH) · collab

RandomizedCrossoverDouble-blindTreatment

Summary

This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.

Timeline

Start: 2004-03
Primary completion: 2005-10
Completion: 2005-10

Publications

Background Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl). 2004 Jun;174(1):54-64. doi: 10.1007/s00213-003-1750-1. Epub 2004 Feb 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GTS-21	Small molecule	75 mg	Oral
Subject	GTS-21	Small molecule	150 mg	Oral

Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

Summary

Timeline

Publications

Drugs

Indications